Healthcare


 Why Mayne Pharma’s Court Victory Is Turning Heads

Why Mayne Pharma’s Court Victory Is Turning Heads

May 22, 2026 03:09 PM AEST| By Sam

Mayne Pharma returned to market focus after securing a major court costs order amid growing attention on healthcare regulation and pharmaceutical sector governance.

 Why This Healthcare Tech Deal Is Turning Heads

Why This Healthcare Tech Deal Is Turning Heads

May 22, 2026 12:32 PM AEST| By Sam

Alcidion attracted renewed market attention after expanding through a Telstra Health deal, highlighting growing momentum across healthcare technology and digital clinical systems.

 Why These ASX 200 Shares Are Back In The Spotlight

Why These ASX 200 Shares Are Back In The Spotlight

May 22, 2026 11:16 AM AEST| By Sam

CSL, Megaport and Treasury Wine Estates are attracting renewed market attention as investors search for ASX recovery opportunities.

 Why Oceania Healthcare’s Dividend Pause Is Raising Eyebrows

Why Oceania Healthcare’s Dividend Pause Is Raising Eyebrows

May 22, 2026 10:06 AM AEST| By Sam

Oceania Healthcare improved earnings, reduced debt and strengthened care margins, but ongoing cash flow pressure continues delaying dividend payments.

 IXICO Expands Reach in Neuroscience Research Space

IXICO Expands Reach in Neuroscience Research Space

May 21, 2026 07:44 PM AEST| By Vivek Singh

IXICO (LSE:IXI) advances its neuroscience imaging capabilities with fresh healthcare research contracts supporting Alzheimer’s and Huntington’s disease development programmes.

 Avecho Biotechnology Advances Insomnia Program Momentum

Avecho Biotechnology Advances Insomnia Program Momentum

May 21, 2026 04:45 PM AEST| By Sam

Avecho Biotechnology advances its insomnia treatment program after completing a major clinical trial milestone, strengthening attention on Australia’s evolving cannabidiol healthcare market.

 ASX Healthcare Stocks: Why AFT’s Revenue Ambition Is Turning Heads

ASX Healthcare Stocks: Why AFT’s Revenue Ambition Is Turning Heads

May 21, 2026 02:21 PM AEST| By Sam

AFT Pharmaceuticals gained market attention after record earnings and a fresh revenue direction, highlighting healthcare innovation, and expanding international operations within the pharmaceutical sector.

 AFT Pharmaceuticals Profit Surges As Global Expansion Gains Momentum

AFT Pharmaceuticals Profit Surges As Global Expansion Gains Momentum

May 21, 2026 01:26 PM AEST| By Sam

Highlights,AFT Pharmaceuticals reported strong profit growth supported by rising revenue.,Expansion across international healthcare markets continued gaining traction.,Management expects further earnings and sales momentum during the current financia...

 Avecho ASX 200 Reports Progress in Insomnia Clinical Trial

Avecho ASX 200 Reports Progress in Insomnia Clinical Trial

May 21, 2026 01:10 PM AEST| By Sam

Avecho completed the treatment phase for its late-stage insomnia study while advancing interim review procedures linked to pharmaceutical development activities.

 CSL’s Canadian HEMGENIX Milestone Could Shift Market Attention Toward Gene Therapy Growth

CSL’s Canadian HEMGENIX Milestone Could Shift Market Attention Toward Gene Therapy Growth

May 21, 2026 11:18 AM AEST| By Sam

CSL’s Canadian reimbursement milestone has renewed attention on the company’s gene therapy growth strategy and commercial execution.

 Why This ASX Healthcare Stock Is Gaining Fresh Attention

Why This ASX Healthcare Stock Is Gaining Fresh Attention

May 21, 2026 10:56 AM AEST| By Sam

AFT Pharmaceuticals strengthened investor attention after reporting stronger earnings growth and ongoing international healthcare expansion.

 AFT Pharma ASX 300 Records Strong FY Twenty Six Profit

AFT Pharma ASX 300 Records Strong FY Twenty Six Profit

May 21, 2026 09:59 AM AEST| By Sam

AFT Pharmaceuticals recorded a landmark FY twenty six financial outcome with wider international operations, stronger medicine distribution, and expanding healthcare market activity.

 Why Is CSL Staying in Focus Across the ASX 200 Market?

Why Is CSL Staying in Focus Across the ASX 200 Market?

May 21, 2026 09:52 AM AEST| By Sam

CSL remained closely watched across the healthcare sector as biotechnology and pharmaceutical companies continued attracting attention within the ASX market.

 Could All Ordinaries TGA Approval Lift OncoSil Focus?

Could All Ordinaries TGA Approval Lift OncoSil Focus?

May 20, 2026 06:36 PM AEST| By Sam

OncoSil strengthened healthcare sector visibility after securing TGA approval for its oncology treatment device as biotechnology innovation and medical technology activity remained central industry themes.

 Why These ASX Penny Stocks Are Drawing Fresh Attention

Why These ASX Penny Stocks Are Drawing Fresh Attention

May 20, 2026 04:23 PM AEST| By Sam

Audinate Group, Alcidion Group, and Austin Engineering are gaining attention as Australian investors focus on financially stable smaller companies operating across technology, healthcare, and mining-linked sectors amid cautious market conditions.

 Cracks Beneath the ASX 200 Calm Are Getting Hard to Ignore

Cracks Beneath the ASX 200 Calm Are Getting Hard to Ignore

May 20, 2026 04:02 PM AEST| By Sam

Australian shares may appear stable on the surface, but weakness across retail, healthcare, banking and technology stocks reveals growing pressure from inflation, oil prices and slowing consumer demand.

 Could ASX 300 Oncology Progress Lift Nyrada Focus?

Could ASX 300 Oncology Progress Lift Nyrada Focus?

May 20, 2026 03:15 PM AEST| By Sam

Nyrada advanced oncology-focused Xolatryp research and US patent activity as biotechnology innovation and pharmaceutical intellectual property discussions strengthened across the healthcare sector.

 Biotech Buzz Builds as ASX Drug Developers Chase Breakthroughs

Biotech Buzz Builds as ASX Drug Developers Chase Breakthroughs

May 20, 2026 02:35 PM AEST| By Sam

Australian biotech companies are regaining market attention after new clinical trial developments involving cancer and neurological treatment programs boosted sentiment across healthcare-focused ASX small caps.

 ASX 200 Health Tech Share Rebounds As Pro Medicus Returns To Market Spotlight

ASX 200 Health Tech Share Rebounds As Pro Medicus Returns To Market Spotlight

May 20, 2026 09:31 AM AEST| By Sam

Pro Medicus returned to market focus as enterprise imaging demand, US healthcare exposure, and broader digital healthcare trends continued supporting attention toward ASX health-tech shares.

 Why Pro Medicus Shares Are Drawing Market Attention

Why Pro Medicus Shares Are Drawing Market Attention

May 19, 2026 06:36 PM AEST| By Sam

Explore how Pro Medicus is strengthening its position in healthcare imaging technology through innovation, financial resilience, and growing global demand within the Australian share market.

AU_advertise

Advertise your brand on Kalkine Media

Recent Articles






Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.